Increasing demand for non-invasive biomarkers to catapult growth in the exosome diagnostic and therapeutic market. The market size is expected to increase from US$ 88.56 million in 2024 to US$ 211.6 million by 2034, at a 9.10% CAGR.
| Attributes | Key Insights |
|---|---|
| Estimated Exosomes Diagnostic and Therapeutic Market Size (2024E) | US$ 88.56 million |
| Projected Exosomes Diagnostic and Therapeutic Market Valuation (2034F) | US$ 211.6 million |
| Value-based CAGR (2024 to 2034) | 9.10% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The healthcare sector is facing pressure to reduce the prices of healthcare services to increase their accessibility among the rising patient population. In this regard, laboratories are adopting solutions that are integrated with informatics. This helps boost productivity with the help of available resources.
Manufacturers are taking an opportunistic approach by offering such healthcare facilities with additional services and support in terms of diagnostic test products. Consequently, contributes to market growth.
Key players are also capitalizing on the growing demand for non-invasive tests to diagnose cancer. For this, they continue to maintain partnerships with academic institutes to develop novel non-invasive diagnostics.
| Leading Application | Diagnostics |
|---|---|
| Value Share (2024) | 68.0% |
Based on application, the exosome-based diagnostics segment acquired a massive value share of 68% in 2023. Significant use of exosomes for diagnostic purposes can be attributed to their effective delivery of specific disease cells like nucleic acids and proteins. Exosome diagnostic tests are presently being developed for several diseases like infectious diseases, cancer, and neurological disorders.
| Leading Product Type | Instruments |
|---|---|
| Value Share (2024) | 25.0% |
By product type, the instruments segment accounts for a prominent share of 25% in the exosomes diagnostic and therapeutic market. The segment is driven by rapid advancements in research and development activities in the healthcare sector. Growth in the count of manufacturers providing instruments for diagnostic and therapeutic is also propelling the segment expansion.
Principal Consultant
| Countries | Forecast CAGR (2024 to 2034) |
|---|---|
| The United States | 4.50% |
| Canada | 5.0% |
| Germany | 3.80% |
| China | 10.0% |
| India | 9.50% |
Market players are exploiting the potential for the exosome diagnostic and therapeutic industry in the United States, which is estimated to grow at 4.5% CAGR over the forecast period. Exosomes have been receiving significant traction over the past few years due to their remarkable therapeutic possibilities.
They can be harnessed for focused delivery of therapeutic agents, like nucleic acids, proteins, and pharmaceuticals, nucleic acids, throughout biological barriers. This attribute holds a lot of potential in precision medicine applications, especially in cancer therapy.
Numerous cutting-edge technologies and the latest strategies have been developed to harness the capability of exosomes to enhance the efficiency and precision of cancer detection. These approaches can revolutionize cancer diagnostics, offering non-invasive, more precise, and early detection methods.
Liquid biopsies are one such disruptive strategy in cancer treatment, which uses non-invasive collection and investigation of exosomes from body fluids like urine, blood, and saliva.
The rapid increase in cancer patients and surging funding for cancer-related research are expected to continue supporting the exosome diagnostic and therapeutic industry in the United States.
Adoption of exosomes diagnostic and therapeutic in Canada is projected to surge at a CAGR of 5% through 2034. Growth of this industry is increasing as researchers are trying to understand the connection between kidney function and disorders and urinary exosomes since exosomes carry cargo across kidney cells.
The availability, non-invasive nature, and ease of sample collection of urinary exosomes make them remarkable. Non-invasive exosomes offer a cost-effective way to uncover disease causes and therapeutic targets owing to their prognostic and diagnostic sensitivity. Additionally, non-invasive biomarkers have more patient and clinical adoption than their invasive counterparts.
Conveniently distributable and cost-effective distributable urinary indicators are clinically accessible. These factors contribute to the growth of the exosomes diagnostic and therapeutic market.
The scope of exosomes diagnostic and therapeutic in Germany is estimated to expand at a CAGR of 3.80% over the next 10 years. The industry is expected to be propelled by the increasing count of research activities with a focus on applications of exosomes to access the therapeutic effects of stem cells within the country.
Growing demand for advanced diagnostic assays as well as the increasing incidence of cancer in Germany are contributing to exosomes diagnostic and therapeutic market growth. Certain common factors that are compelling growth in the industry include advancements in healthcare systems and surging funding for research and development in Germany.
Investments in the Indian market are projected to rise at a CAGR of 9.5% in the following decade. Increasing cases of diseases like infectious disorders, cancer, and neurological diseases in India are raising the demand for more effective treatment and diagnostic tools offered by exosomes.
Ongoing technological advancements like proteomic analysis and high-throughput techniques are facilitating the characterization and identification of exosomes. Along with this, technological progress is helping in the development of diagnostic therapies and tools based on exosomes.
Surging investments from government agencies, private investors, and pharmaceutical firms are promoting research and growth in exosome diagnostics and therapeutics. With improving regulatory acceptance for exosome-based products, the market is set for significant expansion.
Demand for exosome diagnostic and therapeutic in China is expected to rise at a CAGR of 10% over the forecast period. The market is driven by an increase in clinically researched and perceived applications of exosomes as smart nano-platforms for therapy and diagnosis in the country. Additionally, market players in China are increasing their efforts to exhibit the utility of exosomes in non-invasive testing to accelerate its adoption.
The exosome diagnostic and therapeutic industry is experiencing a high level of competition, thanks to the growing count of companies manufacturing exosome-based products. All known companies in the market are covered below. Along with the companies, the technology that they are working on is also described. The following companies may or may not be working with any regulatory agencies, however, many of them do.
AcouSort AB
It is a Swedish firm that is introducing a revolutionary acoustofluidic technology and working on exosome-based diagnostics. The European Innovation Council (EIC) rewarded AcouSort and its project partners with a total of US$ 2.5 million to create acoustofluidic thin-film actuated chip to separate exosomes from blood.
Aethlon Medical, Inc.
It is a United States-based company that focuses on addressing the unmet requirements in the global health and biodefense industry. The firm began its tumor-derived exosome research when the medical community held a view that exosomes are cellular debris.
Fast-forward to the present, a therapeutic to attend to tumor-derived exosomes presents a significant gap in cancer care. Aethlon has shown that Hemopurifier®’s affinity mechanism can detect tumor-derived exosomes behind various forms of cancer, like ovarian, breast, and metastatic melanoma.
AGC Biologics
AGC Biologics came into a service agreement with Japan’s Jikei University in April 2023. This agreement states that AGC Biologics is going to assume a feasibility study and technology transfer for a drug to cure idiopathic pulmonary fibrosis (IPF). Specifically, the ACG scientists are going to focus on recognizing the viability of developing a sample for an exosome-based treatment.
Aruna Bio
The company is leveraging the natural abilities of neural exosomes to pass the blood-brain barrier and elevate the body’s anti-inflammatory, protective, and self-repair mechanisms for neurodegenerative disorders treatment.
Latest Developments in the Exosomes Diagnostic and Therapeutic Market
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
For the year 2024, the exosomes diagnostic and therapeutic industry is estimated to be valued at US$ 88.56 million.
The adoption rate of exosomes diagnostic and therapeutic is calculated to be around 9.10% for the forecast period.
The market revenue is expected to shoot up to US$ 211.6 million by 2034.
The diagnostics segment grabs a hefty share within the exosomes diagnostic and therapeutic industry.
China is expected to register a significant growth rate in the exosomes diagnostic and therapeutic industry.
Anjarium Biosciences AG, Aruna Bio, and Brexogen are influential players in the exosome diagnostic and therapeutic industry.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Component
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Component, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Component, 2024 to 2034
5.3.1. Instruments
5.3.2. Software
5.3.3. Reagents & Kits
5.4. Y-o-Y Growth Trend Analysis By Component, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Component, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2024 to 2034
6.3.1. Diagnostics
6.3.2. Therapeutic
6.4. Y-o-Y Growth Trend Analysis By Application, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Application, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2024 to 2034
7.3.1. Hospitals
7.3.2. Cancer Institutes
7.3.3. Diagnostic Centres
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By End User, 2019 to 2023
7.5. Absolute $ Opportunity Analysis By End User, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Component
9.2.3. By Application
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Component
9.3.3. By Application
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Component
10.2.3. By Application
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Component
10.3.3. By Application
10.3.4. By End User
10.4. Key Takeaways
11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Component
11.2.3. By Application
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Component
11.3.3. By Application
11.3.4. By End User
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Component
12.2.3. By Application
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Component
12.3.3. By Application
12.3.4. By End User
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Component
13.2.3. By Application
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Component
13.3.3. By Application
13.3.4. By End User
13.4. Key Takeaways
14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Component
14.2.3. By Application
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Component
14.3.3. By Application
14.3.4. By End User
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Component
15.2.3. By Application
15.2.4. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Component
15.3.3. By Application
15.3.4. By End User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Market Share Analysis, 2023
16.1.1.1. By Component
16.1.1.2. By Application
16.1.1.3. By End User
16.2. Canada
16.2.1. Market Share Analysis, 2023
16.2.1.1. By Component
16.2.1.2. By Application
16.2.1.3. By End User
16.3. Brazil
16.3.1. Market Share Analysis, 2023
16.3.1.1. By Component
16.3.1.2. By Application
16.3.1.3. By End User
16.4. Mexico
16.4.1. Market Share Analysis, 2023
16.4.1.1. By Component
16.4.1.2. By Application
16.4.1.3. By End User
16.5. Germany
16.5.1. Market Share Analysis, 2023
16.5.1.1. By Component
16.5.1.2. By Application
16.5.1.3. By End User
16.6. UK
16.6.1. Market Share Analysis, 2023
16.6.1.1. By Component
16.6.1.2. By Application
16.6.1.3. By End User
16.7. France
16.7.1. Market Share Analysis, 2023
16.7.1.1. By Component
16.7.1.2. By Application
16.7.1.3. By End User
16.8. Spain
16.8.1. Market Share Analysis, 2023
16.8.1.1. By Component
16.8.1.2. By Application
16.8.1.3. By End User
16.9. Italy
16.9.1. Market Share Analysis, 2023
16.9.1.1. By Component
16.9.1.2. By Application
16.9.1.3. By End User
16.10. Poland
16.10.1. Market Share Analysis, 2023
16.10.1.1. By Component
16.10.1.2. By Application
16.10.1.3. By End User
16.11. Russia
16.11.1. Market Share Analysis, 2023
16.11.1.1. By Component
16.11.1.2. By Application
16.11.1.3. By End User
16.12. Czech Republic
16.12.1. Market Share Analysis, 2023
16.12.1.1. By Component
16.12.1.2. By Application
16.12.1.3. By End User
16.13. Romania
16.13.1. Market Share Analysis, 2023
16.13.1.1. By Component
16.13.1.2. By Application
16.13.1.3. By End User
16.14. India
16.14.1. Market Share Analysis, 2023
16.14.1.1. By Component
16.14.1.2. By Application
16.14.1.3. By End User
16.15. Bangladesh
16.15.1. Market Share Analysis, 2023
16.15.1.1. By Component
16.15.1.2. By Application
16.15.1.3. By End User
16.16. Australia
16.16.1. Market Share Analysis, 2023
16.16.1.1. By Component
16.16.1.2. By Application
16.16.1.3. By End User
16.17. New Zealand
16.17.1. Market Share Analysis, 2023
16.17.1.1. By Component
16.17.1.2. By Application
16.17.1.3. By End User
16.18. China
16.18.1. Market Share Analysis, 2023
16.18.1.1. By Component
16.18.1.2. By Application
16.18.1.3. By End User
16.19. Japan
16.19.1. Market Share Analysis, 2023
16.19.1.1. By Component
16.19.1.2. By Application
16.19.1.3. By End User
16.20. South Korea
16.20.1. Market Share Analysis, 2023
16.20.1.1. By Component
16.20.1.2. By Application
16.20.1.3. By End User
16.21. GCC Countries
16.21.1. Market Share Analysis, 2023
16.21.1.1. By Component
16.21.1.2. By Application
16.21.1.3. By End User
16.22. South Africa
16.22.1. Market Share Analysis, 2023
16.22.1.1. By Component
16.22.1.2. By Application
16.22.1.3. By End User
16.23. Israel
16.23.1. Market Share Analysis, 2023
16.23.1.1. By Component
16.23.1.2. By Application
16.23.1.3. By End User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Component
17.3.3. By Application
17.3.4. By End User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Thermo Fisher Scientific
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. NanoSomix
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. NX Pharmagen
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Malvern Instruments
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Capricor Therapeutic
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Exosome Diagnostics
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Exiqon A/S
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. System Biosciences
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Exosome Sciences
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Aegle Therapeutic
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. AMS Biotechnology
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.12. Miltenyi Biotec
18.1.12.1. Overview
18.1.12.2. Product Portfolio
18.1.12.3. Profitability by Market Segments
18.1.12.4. Sales Footprint
18.1.12.5. Strategy Overview
18.1.12.5.1. Marketing Strategy
18.1.13. Codiak BioSciences Inc.
18.1.13.1. Overview
18.1.13.2. Product Portfolio
18.1.13.3. Profitability by Market Segments
18.1.13.4. Sales Footprint
18.1.13.5. Strategy Overview
18.1.13.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Exosomes Diagnostic and Therapeutic Market
